Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Recent & Breaking News (NDAQ:GRCE)

A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Benzinga.com  October 2, 2018

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

GlobeNewswire October 1, 2018

Acasti Pharma Appoints Jean-François Boily as Vice President of Finance

GlobeNewswire September 24, 2018

Acasti Pharma Provides Clinical and Market Update

GlobeNewswire September 18, 2018

Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM

GlobeNewswire August 29, 2018

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019

GlobeNewswire August 14, 2018

Acasti Pharma Announces Mailing of Management Information Circular and Amendment to Stock Option Plan

GlobeNewswire July 31, 2018

Acasti Pharma Awarded Composition-of-Matter Patent by the U.S. Patent and Trademark Office

GlobeNewswire July 24, 2018

Acasti Pharma Announces Annual Performance Grants of Stock Options, Amendment of Stock Option Plan and Issuance of Common Shares in Payment of Outstanding Interest under Debentures

GlobeNewswire July 2, 2018

Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018

GlobeNewswire June 27, 2018

Acasti Pharma Reports on Positive Feedback Following Today’s Presentation at the XVIII International Symposium on Atherosclerosis

GlobeNewswire June 11, 2018

Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis

GlobeNewswire June 6, 2018

Acasti Pharma Appoints Brian Groch as Chief Commercial Officer

GlobeNewswire June 4, 2018

Acasti Pharma Retains Crescendo Communications for Investor Relations Services in the United States

GlobeNewswire May 18, 2018

Acasti Pharma Announces Full Exercise of Over-Allotment Option

GlobeNewswire May 14, 2018

Acasti Pharma Announces Closing of $10 Million Underwritten Offering

GlobeNewswire May 9, 2018

Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen

Benzinga.com  April 25, 2018

IIROC Trading Resumption - ACST

Canada NewsWire April 24, 2018

IIROC Trading Halt - ACST

Canada NewsWire April 23, 2018

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

GlobeNewswire April 2, 2018